Immunohistochemistry OLIG2 Test: Advanced Brain Tumor Diagnosis
Understanding the Immunohistochemistry OLIG2 Test
The Immunohistochemistry OLIG2 Test represents a cutting-edge diagnostic approach in neuro-oncology that specifically targets the OLIG2 protein biomarker. This sophisticated testing methodology utilizes advanced immunohistochemistry techniques to detect the presence of OLIG2, a crucial transcription factor involved in oligodendrocyte development and differentiation. The test plays a vital role in modern cancer diagnostics by providing precise identification and classification of central nervous system tumors, particularly gliomas and oligodendrogliomas.
At General Genetics Corporation, we employ state-of-the-art immunohistochemistry protocols to ensure accurate and reliable OLIG2 detection. This test has revolutionized brain tumor diagnosis by offering pathologists and oncologists critical information that directly impacts treatment decisions and patient outcomes. The ability to precisely identify tumor types through OLIG2 expression patterns has become an essential component of comprehensive neuropathological evaluation.
What the OLIG2 Test Measures and Detects
The Immunohistochemistry OLIG2 Test specifically measures the expression levels of the Oligodendrocyte Transcription Factor 2 (OLIG2) protein in tumor tissue samples. This biomarker detection provides valuable insights into:
- Identification of oligodendroglial lineage tumors
- Differentiation between various glioma subtypes
- Detection of oligodendrocyte precursor cells
- Assessment of tumor origin and cellular composition
- Complementary information for 1p/19q co-deletion analysis
OLIG2 serves as a nuclear marker that is highly expressed in oligodendrogliomas and other glial tumors, making it an invaluable tool for precise tumor classification. The test utilizes specific antibodies that bind to OLIG2 proteins, creating visible staining patterns that pathologists can interpret to determine tumor characteristics and behavior.
Who Should Consider the OLIG2 Test
The Immunohistochemistry OLIG2 Test is recommended for patients presenting with specific clinical scenarios and symptoms:
Primary Indications:
- Patients with suspected brain tumors or mass lesions
- Individuals experiencing neurological symptoms such as seizures, headaches, or cognitive changes
- Cases requiring differential diagnosis between glioma subtypes
- Patients with previously diagnosed brain tumors needing precise classification
- Those being evaluated for targeted therapy options
Symptoms and Clinical Presentations:
- Unexplained neurological deficits
- Progressive headaches with imaging abnormalities
- Seizures of recent onset
- Cognitive or personality changes
- Motor or sensory disturbances
- Visual or speech abnormalities
Benefits of Taking the OLIG2 Test
Choosing the Immunohistochemistry OLIG2 Test provides numerous advantages for both patients and healthcare providers:
Diagnostic Precision:
- Accurate classification of brain tumor types
- Enhanced differential diagnosis capabilities
- Reduced diagnostic uncertainty
- Comprehensive tumor characterization
Treatment Planning Advantages:
- Informs targeted therapy selection
- Helps predict treatment response
- Guides surgical decision-making
- Supports personalized medicine approaches
Prognostic Value:
- Provides insights into tumor behavior
- Helps estimate disease progression
- Supports long-term management planning
- Facilitates appropriate follow-up strategies
Understanding Your Test Results
Interpreting Immunohistochemistry OLIG2 Test results requires specialized expertise, but here’s a general guide to understanding your findings:
Positive OLIG2 Expression:
- Indicates presence of oligodendroglial differentiation
- Supports diagnosis of oligodendroglioma or related tumors
- Suggests specific tumor lineage and characteristics
- May influence treatment approach and prognosis
Negative OLIG2 Expression:
- Does not necessarily rule out glial tumors
- May indicate different tumor types or subtypes
- Requires correlation with other diagnostic markers
- Should be interpreted in clinical context
Interpretation Considerations:
- Results are evaluated by board-certified pathologists
- Findings are integrated with clinical presentation and imaging
- Multiple factors influence final diagnosis
- Comprehensive report includes detailed explanation
Test Pricing and Availability
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Immunohistochemistry OLIG2 Test | $88 USD | $126 USD |
Nationwide Testing Network
General Genetics Corporation maintains testing facilities across the United States, ensuring convenient access to advanced diagnostic services. Our network includes locations in major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, and many other cities. Each facility adheres to the highest standards of quality and utilizes consistent testing protocols to ensure reliable results nationwide.
Take Action for Your Health
Don’t leave your diagnostic needs to chance. The Immunohistochemistry OLIG2 Test provides critical information that can significantly impact your treatment journey and overall outcomes. Our team of specialists is ready to assist you with scheduling, sample collection guidance, and result interpretation.
Book Your Test Today: Call us at +1(267) 388-9828 or visit our website to schedule your Immunohistochemistry OLIG2 Test. Take the first step toward precise diagnosis and personalized treatment planning with confidence in our expertise and commitment to excellence in cancer diagnostics.
Our dedicated patient care coordinators are available to answer your questions, explain the testing process, and help you navigate your diagnostic journey. Trust General Genetics Corporation for accurate, reliable, and timely OLIG2 testing that makes a difference in your healthcare decisions.
